TABLE 2.

Patient and EEG Characteristics

	cEEG	Routine EEG	P
N	7	12
Age at CAR T infusion (mean in years, range)	14.9 (6–22)	8.9 (2–23)	0.025
Female sex	4 (57%)	4 (33%)	0.311
History of epilepsy	0 (0%)	1 (8%)	0.433
Neurotoxicity CTCAE score (mean, range 0–5)	3.6	2.8	0.108
CRS grade (mean, range 0–2)	1.1	1.3	0.410
Acute MRI abnormality	5/7 (71%)	6/8 (75%)	0.876
Received steroids	7	8	0.086
Received tocilizumab	6	7	0.216
EEG duration (mean, range)	48 hours (14–75 hours)	45 minutes (30–75 minutes)	<0.001
Clinical seizure ≤28 days after CAR T cell infusion	5 (71%)	3 (25%)	0.048
Interictal epileptiform discharges	4 (57%)	1 (8%)	0.020
Seizures on EEG	4 (57%)	0 (0%)	0.003
Electrographic-only seizures	3 (43%)	0 (0%)	0.013
Number of acute antiseizure medications (range)	2.0 (1–4)	1.2 (1–2)	0.050
Number of antiseizure medications after day 28 (range)	0.85 (0–2)	0.25 (0–1)	0.042
Seizures after day 28	1 (14%)	0 (0%)	0.179

CTCAE, common terminology criteria of adverse events, designating most severe score of any symptom throughout the patient’s course. CRS, cytokine release syndrome (none is coded as 0, mild = 1, severe = 2).

CAR, Chimeric Antigen Receptor; MRI, magnetic resonance imaging.

Bolded items denote variables which are statistically significantly different between groups, P < 0.05.